Atorvastatin advertising misled over benefits for women, study claimsBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2209 (Published 22 October 2008) Cite this as: BMJ 2008;337:a2209
- Roger Dobson
Advertising of the world’s best selling drug failed to disclose the absence of benefits for women, who should be entitled to compensation to recoup the costs of treatment, claim experts in epidemiology and law in a new analysis.
They argue that unqualified claims of protection against heart attacks made in advertisements for the lipid lowering drug atorvastatin (which is made by Pfizer and sold as Lipitor) may be misleading and that the advertising raises concerns about the way the US Food and Drug Administration regulates drugs (Journal of Empirical Legal Studies 2008;5:507-50, doi:10.1111/j.1740-1461.2008.00132.x)
The authors, Theodore Eisenberg, a professor of law at Cornell Law School, and Martin Wells, professor of clinical epidemiology at Cornell University Weill Medical College, claim that a substantial portion of the multibillion dollar market in statins may be made up of users for whom the drugs offer no benefit.
They add that remedies to recover costs should …
Log in using your username and password
Log in through your institution
Sign up for a free trial